Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Hope S Rugo, MD

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 2: Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Hope S Rugo, MD 

CME information and select publications